A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Status:
Withdrawn
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of four dose
levels of liposomal doxorubicin, melphalan, and bortezomib in patients with
relapsed/refractory MM and to identify a maximum tolerated dose (MTD) of this combination.